84
Participants
Start Date
June 15, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Oral Vancomycin
The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
Placebo
The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
RECRUITING
Fondazione IRCCS San Gerardo dei Tintori, Monza
Genetic s.p.a.
UNKNOWN
University of Milano Bicocca
OTHER